Cubist Systematic Strategies LLC raised its stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) by 259.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,966 shares of the biopharmaceutical company’s stock after purchasing an additional 41,130 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.08% of CymaBay Therapeutics worth $412,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the business. Russell Investments Group Ltd. acquired a new stake in shares of CymaBay Therapeutics in the second quarter worth $25,000. Point72 Hong Kong Ltd lifted its holdings in CymaBay Therapeutics by 1,070.1% during the second quarter. Point72 Hong Kong Ltd now owns 10,402 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 9,513 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in CymaBay Therapeutics during the second quarter valued at $42,000. Bank of Montreal Can lifted its holdings in CymaBay Therapeutics by 698.4% during the second quarter. Bank of Montreal Can now owns 13,309 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 11,642 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its holdings in CymaBay Therapeutics by 20.0% during the second quarter. State Board of Administration of Florida Retirement System now owns 14,594 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 2,430 shares in the last quarter. Institutional investors and hedge funds own 83.44% of the company’s stock.
NASDAQ:CBAY opened at $5.74 on Friday. CymaBay Therapeutics, Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $9.06. The stock has a market cap of $395.41 million, a PE ratio of -6.11 and a beta of 1.47. The firm’s fifty day simple moving average is $7.15 and its 200-day simple moving average is $6.23.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). On average, analysts forecast that CymaBay Therapeutics, Inc. will post -0.71 EPS for the current year.
CBAY has been the topic of several research reports. SVB Leerink raised their price target on shares of CymaBay Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Friday, November 6th. BidaskClub cut shares of CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 25th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their price target on shares of CymaBay Therapeutics from $9.00 to $10.00 in a research report on Monday, November 30th. B. Riley lifted their price target on shares of CymaBay Therapeutics from $9.00 to $13.00 in a research report on Wednesday, September 9th. Finally, ValuEngine cut shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.18.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: Consumer behavior in bull markets
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.